poli
llactic
acid
pla
wide
use
variou
biomed
applic
biodegrad
biocompat
nontox
properti
variou
method
emuls
salt
precipit
use
make
better
pla
micro
nanoparticl
formul
wide
use
control
drug
deliveri
system
therapeut
molecul
includ
protein
gene
vaccin
anticanc
drug
even
though
plabas
particl
challeng
overcom
low
drug
load
capac
low
encapsul
effici
termin
steril
continu
innov
particul
formul
lead
develop
clinic
use
formul
nanoparticl
avail
bulk
surfac
properti
modifi
bulk
modif
method
includ
blend
differ
polym
plastic
copolymer
crosslink
surfac
modif
method
includ
surfac
coat
entrap
plasma
treatment
supplement
biomateri
poli
ethylen
glycol
peg
polysaccharid
extracellular
matrix
ecm
protein
use
coat
pla
micro
nanoparticl
modif
design
achiev
high
drug
encapsul
effici
load
control
drug
releas
rate
follow
section
cover
differ
prepar
techniqu
make
pla
micro
nanoparticl
applic
handl
challeng
strategi
singl
emulsionextract
method
challeng
poor
encapsul
hydrophil
drug
due
diffus
dispers
emulsifi
oil
phase
aqueou
continu
phase
thu
doubleemulsionextract
method
frequent
use
improv
encapsul
effici
water
solubl
drug
peptid
protein
case
solidoilwat
sow
emuls
use
high
drug
load
water
solubl
peptid
insulin
involv
addit
watersolubl
drug
solut
organ
polym
solut
high
energi
stir
form
wo
revers
ow
emuls
wo
emuls
ad
second
water
phase
contain
stabil
stir
result
format
wow
owo
emuls
organ
solvent
remov
reduc
pressur
vacuum
produc
polym
particl
harvest
particl
thoroughli
wash
use
pure
water
buffer
remov
residu
raw
materi
lyophil
sever
paramet
adjust
optim
characterist
particl
prepar
doubl
emuls
method
includ
amount
hydrophil
drug
ad
polym
concentr
type
solvent
stabil
concentr
volum
second
aqueou
phase
stir
rate
variabl
fig
show
singl
doubl
emuls
process
oil
emulsifi
water
one
exampl
pla
three
differ
molecular
weight
use
prepar
microparticl
contain
prilocain
prl
aminoamid
type
local
anesthet
prlload
pla
microparticl
prepar
wow
doubl
emuls
method
particl
size
sem
imag
releas
profil
three
differ
type
pla
microparticl
shown
fig
fig
respect
altern
wide
appli
emulsionbas
techniqu
saltingout
method
method
involv
addit
polym
drug
solut
watermisc
solvent
aceton
acetonitril
tetrahydrofuran
aqueou
solut
contain
saltingout
agent
eg
magnesium
chlorid
calcium
chlorid
colloid
stabil
polyvinylpyrrolidon
high
speed
stir
fig
ow
emuls
dilut
larg
amount
water
induc
format
particl
enhanc
diffus
miscibl
solvent
water
phase
particl
purifi
harvest
centrifug
crossflow
filtrat
one
import
advantag
method
minim
tension
load
protein
salt
need
heat
process
thu
may
use
heat
sensit
drug
encapsul
salt
process
requir
optim
process
condit
eg
salt
type
concentr
type
polym
solvent
ratio
compound
order
obtain
microparticl
nanoprecipit
method
rel
easi
reproduc
techniqu
prepar
pla
base
nanoparticl
nanoprecipit
one
step
process
also
known
solvent
displac
method
fig
advantag
method
narrow
size
distribut
less
toxic
ecofriendli
solvent
low
energi
sourc
stir
devic
nanoprecipit
method
appli
variou
way
direct
pour
antisolv
eg
water
phase
organ
solut
ii
slow
dropwis
addit
water
organ
solut
iii
direct
pour
organ
solut
water
phase
iv
dilut
polymer
dispers
phase
use
antisolv
solvent
remov
suspens
reduc
pressur
vacuum
variabl
key
paramet
form
nanoparticl
inject
rate
organ
phase
antisolv
phase
affect
particl
size
mix
rate
affect
particl
size
drug
encapsul
yield
type
organ
solvent
also
affect
size
encapsul
effici
particl
typic
solvent
use
nanoprecipit
aceton
acetonitril
dimethylacetamid
dimethylformamid
dimethylsulfoxid
dmso
nmp
peg
tetrahydrofuran
aceton
prefer
solvent
usual
binari
mixtur
solvent
use
eg
acetoneethanol
factor
drug
polym
ratio
surfact
antisolv
phase
volum
ratio
difficulti
face
method
choic
combin
drugpolymersolventnonsolv
system
usual
call
ouzo
region
nanoparticl
would
form
high
drug
encapsul
effici
produc
success
nanoparticl
howev
restrict
narrow
condit
ouzo
region
beyond
ouzo
region
microparticl
rather
nanoparticl
produc
improv
load
procain
hydrochlorid
water
solubl
drug
polym
nanoparticl
achiev
increas
aqueou
phase
ph
replac
procain
hydrochlorid
procain
dihydr
base
docetaxel
dtx
load
nanoparticl
prepar
nanoprecipit
method
use
polydopaminemodifi
tocopherol
polyethylen
glycol
succin
tpg
pla
distribut
nanoparticl
size
around
nm
dtx
load
pla
nanoparticl
reduc
tumor
size
significantli
hepatomabear
nude
mice
fig
dialysi
effect
simpl
method
form
small
size
narrowli
distribut
nanoparticl
similar
nanoprecipit
polym
dissolv
organ
solvent
place
dialysi
tube
dialysi
perform
nonsolv
miscibl
organ
solvent
organ
solvent
displac
nonsolv
result
loss
polym
solubl
subsequ
format
polym
aggreg
nanoparticl
homogen
suspens
collect
fulli
displac
organ
solvent
nonsolv
fig
particl
analyz
sem
largest
diamet
make
pla
solut
signific
differ
pla
solut
fig
situ
form
depot
use
site
form
microparticl
micro
depot
approach
overcom
drawback
convent
techniqu
includ
manufactur
cost
complex
method
eg
dri
resuspens
drugpolym
solut
administ
via
inject
target
site
precipit
implant
form
microparticl
fig
concept
employ
fdaapprov
longact
releas
product
drugpolym
solut
dissolv
watermisc
solvent
nmp
dmso
toxic
solvent
must
examin
select
solvent
show
lower
myotox
situ
implant
situ
microparticl
watermisc
solvent
result
harden
emuls
droplet
vivo
solvent
remov
process
may
respons
high
burst
releas
safeti
issu
may
limit
type
oil
eg
paraffinminer
oil
use
deliveri
leuprolid
acet
month
base
situ
form
microparticl
formul
convent
formul
two
syringeconnector
system
solut
leuprolid
plga
pla
nmp
emulsifi
extern
oil
phase
situ
form
plga
microparticl
show
high
initi
releas
high
poros
fig
situ
form
pla
microparticl
exhibit
much
lower
initi
releas
slow
continu
drug
releas
fig
melt
techniqu
provid
anoth
option
encapsul
drug
polym
melt
process
avoid
use
organ
solvent
drug
dispers
polym
melt
result
drugpolym
melt
solidifi
cool
water
phase
cool
chamber
dri
air
flow
fig
drugpolym
melt
cool
ground
mill
form
particl
spheric
particl
smaller
distribut
desir
ground
melt
emulsifi
hot
solut
contain
emulsifi
hot
gel
limit
approach
thermal
treatment
drug
multitud
step
obtain
smooth
microparticl
supercrit
fluid
dens
ga
technolog
offer
interest
effect
techniqu
particl
product
avoid
drawback
tradit
method
supercrit
fluid
method
use
environment
friendli
solvent
potenti
produc
nanoparticl
high
puriti
residu
solvent
two
princip
process
develop
product
nanoparticl
use
supercrit
fluid
rapid
expans
supercrit
solut
ress
rapid
expans
supercrit
solut
liquid
solvent
resolv
fig
limit
ress
use
low
concentr
low
molecular
weight
pla
hard
control
particl
qualiti
size
morpholog
effect
oper
condit
pressur
flow
rate
concentr
drug
polym
evalu
use
differ
size
morpholog
particl
pla
particl
present
mean
diamet
tabl
fig
microfluid
techniqu
fabric
uniform
biodegrad
plabas
particl
implant
uniform
particl
may
allow
precis
control
releas
system
size
particl
primari
determin
drug
releas
kinet
droplet
microfluid
deal
discret
droplet
precis
control
volum
composit
restrict
dispers
ideal
templat
fabric
complex
particl
number
microfluid
approach
develop
wide
use
fabric
singl
emuls
doubl
multipl
emuls
fig
polymer
microparticl
gener
fabric
make
ow
emuls
microfluid
devic
polym
dissolv
organ
solvent
oil
phase
droplet
solidif
solvent
evapor
diffus
extract
polym
solut
organ
solvent
fill
tor
yjunction
microfluid
devic
eject
larg
amount
stabil
solut
solvent
diffus
droplet
water
phase
droplet
solidifi
microspher
due
rel
differ
solubl
solvent
water
polym
solut
droplet
eject
stabil
solut
size
particl
determin
properti
solut
densiti
viscos
flow
rate
polym
solut
diamet
nozzl
interfaci
tension
polym
solut
nozzl
tip
similar
limit
method
use
physic
devic
nozzl
channel
templat
mold
fabric
nanoparticl
would
appar
requir
smaller
nozzl
channel
applic
microfluid
base
microparticl
rapidli
grow
develop
control
drug
deliveri
system
use
complex
multifunct
drug
deliveri
system
multi
coreshel
microparticl
develop
microfluid
techniqu
manufactur
process
microparticl
desir
drug
load
releas
kinet
prepar
furthermor
low
cost
high
reproduc
make
technolog
promis
mass
product
specif
drug
deliveri
system
pla
particl
wide
rang
size
made
wow
emuls
produc
threedimension
flow
focus
glass
capillari
devic
droplet
size
usual
control
fluid
rate
orific
size
also
numer
model
drop
gener
flow
focus
devic
develop
understand
mechan
drop
gener
drip
regim
microfluid
techniqu
use
make
polymer
microparticl
two
differ
size
studi
vitro
releas
profil
bupivacain
fig
mono
dispers
particl
prepar
use
microfluid
releas
drug
slowli
similar
size
particl
prepar
use
convent
method
emuls
method
microparticl
manufactur
method
one
paramet
affect
drug
releas
kinet
import
realiz
factor
also
contribut
significantli
drug
releas
profil
hydrogel
templat
method
base
uniqu
properti
physic
gel
undergo
solgel
phase
transit
upon
chang
environment
condit
temperatur
hydrogel
templat
use
produc
particl
homogen
size
first
step
form
certain
pattern
hard
master
templat
warm
aqueou
hydrogel
solut
eg
gelatin
solut
pour
top
master
templat
templat
place
low
temperatur
condit
imprint
templat
form
hydrogel
mold
solidifi
mold
peel
polymerdrug
solut
suitabl
organ
solvent
pour
hydrogel
mold
evenli
spread
fill
empti
caviti
fill
hydrogel
mold
dri
evapor
solvent
drugload
particl
collect
dissolv
hydrogel
mold
water
particl
wash
water
collect
centrifug
filtrat
gelatin
hydrogel
mold
howev
easi
damag
spread
drugpolym
solut
templat
thu
altern
polym
poli
vinyl
alcohol
pva
use
make
watersolubl
polym
mold
pva
mold
mani
advantag
gelatin
gel
mold
includ
stronger
mechan
strength
eas
handl
make
mold
storag
dri
chamber
use
dri
pva
mold
drugcontain
microparticl
place
distil
water
stir
room
temperatur
pva
mold
dissolv
complet
drugcontain
microparticl
float
freeli
water
microparticl
wash
filter
duallay
mesh
made
stainless
steel
collect
use
centrifug
microparticl
wash
doubl
distil
water
remov
residu
pva
centrifug
supernat
remov
microparticl
vacuum
dri
overnight
fig
show
procedur
fabric
pla
averag
mw
microparticl
produc
use
system
shape
microparticl
cylinder
pva
mold
cylind
pattern
flat
bottom
use
shape
microparaticl
depend
pva
mold
pattern
geometri
microparticl
import
paramet
drug
releas
rate
interact
cell
tissu
cylind
spheric
shape
surfac
area
may
differ
overal
releas
mechan
whether
diffusioncontrol
reservoir
matrix
system
expect
chang
due
shape
thu
shape
microparticl
may
affect
drug
releas
kinet
significantli
sinc
microparticl
size
around
expect
make
differ
administr
homogen
microparticl
fact
make
easier
administr
pva
mold
method
use
make
microparticl
three
poorli
watersolubl
drug
risperidon
ri
methylprednisolon
acet
mpa
paclitaxel
ptx
fabric
microparticl
show
great
conform
origin
templat
design
wide
rang
formul
condit
addit
microparticl
produc
show
narrow
size
distribut
provid
advantag
compar
convent
emulsionbas
method
fig
pva
mold
method
extend
develop
vacuum
spinswip
machin
make
microparticl
effici
larg
quantiti
sever
advantag
templat
base
techniqu
prefer
advantag
monodispers
predetermin
microparticl
dimens
easi
scaleup
reproduc
process
drug
load
pva
mold
approach
high
watersolubl
drug
easi
produc
convent
method
also
limit
howev
size
particl
current
micron
scale
ie
larger
use
uv
lithograph
techniqu
fabric
silicon
water
master
templat
fabric
nanoparticl
requir
prepar
master
templat
nano
size
pattern
pla
micro
nanoparticl
propos
improv
oral
bioavail
poorli
water
solubl
drug
nanoparticl
thought
absorb
gastrointestin
tract
oral
administr
poorli
water
solubl
drug
difficult
make
suitabl
dosag
form
adequ
oral
bioavail
particl
load
poorli
solubl
drug
significantli
increas
drug
dissolut
rate
intestin
special
mechan
absorb
particl
certain
size
nm
particl
show
significantli
higher
uptak
larger
particl
although
gene
therapi
extens
studi
treat
genet
diseas
acquir
diseas
safeti
effici
gene
deliveri
examin
depth
plabas
micro
nanoparticl
shown
particular
promis
improv
protect
plasma
enzym
altern
rout
administr
eg
nasal
oral
pulmonari
mucos
prolong
gene
deliveri
efficaci
cation
pegpla
nanoparticl
one
major
deliveri
system
small
interfer
rna
sirna
system
system
deliveri
small
interf
pololik
kinas
pegpla
nanoparticl
significantli
suppress
tumor
growth
cancer
cell
murin
xenograft
model
sirna
encapsul
pegpla
nanoparticl
shown
success
enter
cell
result
remark
genespecif
knockdown
adult
zebrafish
heart
pla
base
nanoparticl
contain
polyethyleneimin
pei
surfac
use
incorpor
gene
peoplapei
also
use
codeliveri
supercoil
minicircl
mc
dna
vector
dox
nano
carrier
system
advantag
nonfoul
oxazolin
confer
biolog
stabil
pla
provid
hydrophob
dox
encapsul
bioreduct
pei
provid
gene
complex
dual
deliveri
mcdnadox
musmusculu
skinmelanoma
cell
line
atcc
luciferas
tumor
bear
mice
result
significantli
reduc
tumor
size
cancer
cell
viabil
recent
dual
multi
drug
deliveri
system
shown
great
potenti
drug
deliveri
field
cancer
gene
therapi
vaccin
highli
success
prevent
mani
infecti
diseas
use
microparticl
new
vaccin
focus
aid
hepat
b
anthrax
sar
mer
mani
research
group
focus
develop
microparticl
base
singl
shot
vaccin
use
plabas
materi
cell
activ
respons
antigenencapsul
microparticl
increas
fold
antigen
alon
hiv
gag
antigen
coat
pla
nanoparticl
captur
monocytederiv
dendrit
cell
mddc
individu
stimul
mddc
matur
increas
hivspecif
tcell
prolifer
compar
alon
pegplapeg
block
copolym
nanoparticl
evalu
encapsul
hepat
b
surfac
antigen
hbsag
oral
vaccin
deliveri
system
hbsag
encapsul
copolym
pla
nanoparticl
use
adjuvant
gener
immun
stimul
oral
administr
pegplapeg
copolym
nanoparticl
exhibit
effect
level
humor
immun
along
mucos
siga
cellular
immun
respons
h
studi
relationship
plapeg
particl
size
efficaci
transport
across
nasal
mucos
tetanu
toxoid
encapsul
plapeg
particl
differ
size
nm
prepar
wow
doubl
emuls
solvent
evapor
techniqu
nasal
bioavail
tetanu
toxoid
encapsul
nm
nanoparticl
higher
larger
particl
plapeg
nanoparticl
aluminum
phosphat
use
potenti
adjuv
system
use
tetanu
toxoid
encapsul
effici
increas
nearli
plapeg
nanoparticl
compar
convent
vaccin
plapegaluminum
al
plaal
show
surviv
rate
respect
even
day
compar
surviv
rate
convent
tetanu
vaccin
cyclosporin
cya
entrap
pla
micro
nanoparticl
show
enhanc
bioavail
sustain
releas
kinet
extend
period
time
effect
concentr
pla
surfact
aqueou
phase
volum
pla
microspher
size
nimesulid
nonsteroid
antiinflammatori
drug
encapsul
effici
studi
use
particl
made
emuls
method
specif
aqueou
phase
volum
select
small
size
particl
increas
volum
result
microdroplet
coalesc
vitro
releas
albumin
pla
microparticl
sustain
one
month
particl
blend
peg
insulin
load
pegpla
nanoparticl
provid
sustain
releas
two
month
burst
releas
amount
increas
peg
molecular
weight
peg
content
increas
insulinload
pla
base
particl
specif
select
releas
high
ph
condit
might
increas
effect
insulin
blood
stream
ph
one
extens
drug
deliveri
field
cancer
chemotherapi
paclitaxel
load
particl
significantli
enhanc
antitumor
efficaci
compar
free
drug
paclitaxel
load
plapegpla
microparticl
show
sustain
releas
paclitaxel
within
month
vitro
cytotox
test
cancer
cell
line
reveal
plapeg
nanoparticl
compar
free
paclitaxel
exhibit
similar
cytotox
gemcitabin
hydrochlorid
gem
load
pegpla
nanoparticl
zeroord
releas
profil
particl
increas
antitumor
effect
compar
free
drug
differ
cancer
cell
line
show
signific
improv
cell
interact
two
xenograft
murin
model
human
solid
tumor
use
vivo
anticanc
activ
particl
gempegpla
nanoparticl
significantli
inhibit
tumor
growth
mice
surviv
rate
increas
compar
free
drug
docetaxel
tamoxifen
potent
drug
breast
cancer
antagonist
problem
drug
use
combin
differ
metabol
docetaxel
tamoxifen
load
tpgspla
show
signific
reduct
drug
antagon
cell
line
repres
publish
result
plaplga
base
particl
drug
deliveri
system
summar
tabl
variabl
drug
suitabl
method
appli
encapsul
suitabl
method
evalu
load
effici
pharmacokinet
releas
result
current
micro
nanoparticl
product
method
constrain
limit
process
convent
techniqu
sever
disadvantag
includ
rel
high
cost
particl
product
potenti
toxic
solvent
reagent
like
stabil
emulsifi
addit
form
particl
use
high
energi
mechan
mixer
homogen
may
damag
biolog
drug
protein
peptid
macromolecul
difficulti
reproduc
biolog
stabl
particl
low
drug
encapsul
effici
high
energi
mechan
mixer
homogen
gener
high
shear
forc
high
energi
shear
forc
caus
disord
chang
natur
structur
macromolecul
biopharmaceut
protein
drug
may
denatur
exposur
watersolv
interfac
organ
solvent
report
process
small
laboratori
scale
small
test
product
scale
g
larg
product
scale
result
differ
particl
size
distribut
increas
process
volum
solvent
evapor
rate
may
differ
signific
challeng
understand
particl
form
mechan
encapsul
process
physicochem
character
nanoand
microparticl
complet
nanoparticl
sever
uniqu
physicochem
properti
present
difficulti
character
nanoparticl
need
higher
cost
character
method
relat
size
shape
surfac
charg
surfac
area
physicochem
properti
incomplet
character
nanoparticl
may
lead
incomplet
understand
correl
nanoparticl
properti
variou
biolog
effect
properti
nanoparticl
may
easili
chang
surround
environ
blood
stream
cell
type
physicochem
environ
temperatur
ph
pressur
volum
etc
plabas
nanoparticl
need
analyz
dri
lyophil
form
test
media
without
serum
base
cultur
media
complet
character
one
import
consider
make
drug
deliveri
system
steril
plabas
particl
use
steril
method
appli
pla
base
particl
steam
steril
use
pla
base
particl
high
temperatur
pressur
affect
particl
soften
melt
deform
undergo
hydrolysi
heat
steril
expos
particl
high
temperatur
long
period
time
destroy
pla
matrix
structur
drug
ethylen
oxid
eo
known
polym
soften
plastic
residu
eo
ga
caus
mutagen
carcinogen
allergen
effect
gamma
radiat
breakdown
polym
chain
result
decreas
molecular
weight
increas
biodegrad
rate
significantli
alter
drug
releas
profil
therefor
gmp
grade
product
particl
done
asept
process
effect
prevent
contamin
particl
expens
techniqu
manufactur
pla
base
particl
requir
clean
room
control
use
gmp
protocol
variou
particl
product
techniqu
investig
improv
encapsul
effici
drug
optim
scale
process
mass
product
enhanc
reproduc
method
tabl
list
summari
challeng
associ
develop
pla
base
particl
drug
deliveri
applic
one
use
strategi
overcom
certain
challeng
surfac
modif
pla
base
micro
nanoparticl
improv
stabil
particl
surfac
modif
import
escap
immun
system
administr
particl
bloodstream
similarli
strategi
use
make
hydrophil
cloud
around
particl
reduc
uptak
re
system
strategi
compris
surfac
modif
particl
tween
peg
peo
poloxam
poloxamin
polysorb
tpg
function
amino
acid
polysaccharid
prefer
surfac
modif
adsorpt
graft
peg
known
pegyl
surfac
particl
graft
peg
pegcontain
copolym
onto
surfac
particl
augment
blood
circul
halflif
increas
molecular
weight
peg
chain
shown
reduc
opson
particl
improv
retent
circul
addit
peg
may
good
interact
blood
compon
option
copolymer
pgapcl
peg
polym
placopolym
work
well
biocompat
polym
particl
drug
deliveri
system
huge
amount
knowledg
scatter
around
world
data
plabas
micro
nanoparticl
uniqu
fabric
method
drug
use
efficaci
test
method
differ
make
difficult
compar
properti
pla
particl
plga
particl
matter
find
right
formul
specif
applic
time
assembl
data
bank
present
detail
inform
correl
pla
particl
properti
vivo
function
data
bank
propel
systemat
develop
futur
pla
micro
nanoparticl
develop
specif
vivo
applic
drug
releas
profil
prilocaineload
microparticl
ph
phosphat
buffer
total
amount
calcul
averag
valu
encapsul
effici
percentag
obtain
direct
indirect
method
schemat
templatemold
method
process
fabric
pla
microparticl
lee
tabl
investig
plaplga
particl
drug
deliveri
system
plapeg
zidovudin
solvent
evapor
less
phagocytosi
platpg
paclitaxel
modifi
solvent
extractionevapor
initi
burst
follow
sustain
releas
plampeg
salt
less
interact
leukocyt
plapegpla
savoxepin
salt
control
drug
releas
week
pla
bsa
salt
outcoacerv
high
encapsul
effici
accept
burst
releas
pla
cloricromen
nanoprecipit
faster
dissolut
free
drug
pla
tamoxifen
nanoprecipit
signific
therapeut
efficaci
reduc
side
effect
plapluron
steviosid
nanoprecipit
high
potenti
safe
effect
chitosanpla
anthraquinon
nanoprecipit
continu
sustain
releas
ph
depend
releas
profil
plapluron
insulin
dialysi
nanoprecipit
good
control
blood
glucos
concentr
peg
gene
deliveri
dialysi
improv
transfect
activ
pla
hiv
protein
dialysi
induc
mucos
antibodi
product
pla
progesteron
theophyllin
vitamin
spray
dri
altern
method
adv
drug
deliv
rev
author
manuscript
avail
pmc
decemb
